Display options
Cite
Tang K, Schuh AC, Yee KW. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Curr Oncol Rep. 2021;23(10):120doi: 10.1007/s11912-021-01108-9.
Tang, K., Schuh, A. C., & Yee, K. W. (2021). 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Current oncology reports, 23(10), 120. https://doi.org/10.1007/s11912-021-01108-9
Tang, Kenny, et al. "3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?." Current oncology reports vol. 23,10 (2021): 120. doi: https://doi.org/10.1007/s11912-021-01108-9
Tang K, Schuh AC, Yee KW. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Curr Oncol Rep. 2021 Aug 04;23(10):120. doi: 10.1007/s11912-021-01108-9. PMID: 34350512.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol Rep. 2021 Aug 04;23(10):120. doi: 10.1007/s11912-021-01108-9.

3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?.

Current oncology reports

Kenny Tang, Andre C Schuh, Karen Wl Yee

Affiliations

  1. Division of Medical Oncology and Hematology, University Health Network - Princess Margaret Cancer Centre, 610 University Avenue, 700 U 6th Floor, Toronto, Ontario, M5G 2M9, Canada.
  2. Division of Medical Oncology and Hematology, University Health Network - Princess Margaret Cancer Centre, 610 University Avenue, 700 U 6th Floor, Toronto, Ontario, M5G 2M9, Canada. [email protected].

PMID: 34350512 DOI: 10.1007/s11912-021-01108-9

Abstract

PURPOSE OF REVIEW: With the recent approval of multiple new drugs for the treatment of acute myeloid leukemia (AML), the relevance of conventional treatment approaches, such as daunorubicin and cytarabine ("3+7") induction chemotherapy, has been challenged. We review the AML risk stratification, the efficacy of the newly approved drugs, and the role of "3+7".

RECENT FINDINGS: Treatment of AML is becoming more niched with specific subtypes more appropriately treated with gemtuzumab, midostaurin, and CPX-351. Although lower intensity therapies can yield high response rates, they are less efficient at preventing relapses. The only curative potential for poor-risk AML is still an allogeneic stem cell transplant. The number of AML subtypes where 3+7 alone is an appropriate therapeutic option is shrinking. However, it remains the backbone for combination therapy with newer agents in patients suitable for intensive chemotherapy.

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Keywords: Acute myeloid leukemia; CPX-351; Daunorubicin; Midostaurin; Venetoclax; cytarabine; gemtuzumab ozogamicin

Publication Types